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ApoptosisNormal and malignant hematopoiesis are regulated by intercellular communication in the hematopoietic
microenvironments, and both soluble mediators as well as direct cell–cell contact play important functional
roles. Gap junctions are complex membrane structures that transfer molecules between neighboring cells
and thereby alter intracellular signaling and metabolism. The gap junction building blocks, the connexins, are
also involved in gap junction-independent intercellular communication by forming hemichannels that
transfer substances between the intra- and extracellular spaces. Connexins are furthermore involved in cell
regulation as single molecules by modulating intracellular pathways and possibly gene transcription. The
role of connexins in leukemogenesis and leukemic cell functions are not well characterized. In this review,
we describe the known effects of gap junctions and connexins in acute myelogenous leukemia and the
diverse potential of connexins in acute myelogenous leukemia chemosensitivity, intracellular signaling and
cell death regulation.
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The hematopoietic stem cell niche is the microenvironment of
stem cells, their surrounding stromal cells, i.e. ﬁbroblasts, adipocytes,
endothelial and osteoblastic cells and extracellular matrix where the
hematopoiesis takes place. In these niches, the normal hematopoiesis
is regulated by a wide range of soluble mediators and direct cell–cell
interactions. Stromal cells participate through both these mechan-
isms, and endothelial and osteoblastic cells are the main components
Fig. 2. The ﬁgure illustrates the structural relation between a connexin, a CxHc and a
gap junction. Each single CxHc is formed by six connexins. These connexins may be of
the same subtype, e.g. Cx43, or a combination of different subtypes, e.g. Cx43 and Cx45.
Each CxHc of a gap junction is anchored to adjoining cells (see Fig. 1). The two CxHcs of
a single gap junction can be of different types, i.e. one CxHc can be made of one type of
connexins, whereas the other CxHc can be made of another type of connexins.
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stromal cells might therefore be active participants in the develop-
ment of leukemic hematopoiesis as well [1].
Previous in vitro studies have clearly shown that solublemediators
alter acute myelogenous leukemic (AML) cell regulation of prolifer-
ation and apoptosis both when the leukemic cells are cultured alone
[2] and co-cultured with ﬁbroblasts [3], endothelial cells [4] and
osteoblasts [5]. In addition, direct cell–cell interactions between AML
cells and other neighboring cells, including osteoblasts and endothe-
lial cells, will also alter AML cell functions [6,7].
Even though the function of gap junctions and their connexin
building blocks affects the regulations of several cellular functions,
including growth and apoptosis of normal and malignant cells, and
also seems to be important for chemosensitivity, little is known about
their role in leukemogenesis and leukemic cell functions. The aim of
this review is therefore to summarize recent results and describe the
potential roles of connexins in human AML.
2. Gap junctions, hemichannels and connexins
The gap junction (GJ) is one of several structures involved in
intercellular communication. GJs form small channels between
neighboring cells (Fig. 1) that transport molecules and ions with
molecular weights up to approximately 1 kDa, e.g. Ca2+, cyclic
adenosine monophosphate (cAMP) and inositol triphosphate (IP3)
[8,9]. Each of the two communicating cells contributes to these GJs by
their own connexin hemichannels (CxHcs) also named connexons
(Figs. 1 and 2), and each CxHc consists of six transmembrane proteins
called connexins (Cx) (Fig. 2). Twenty-one different human Cxs have
been detected and they are generally named according to their
approximate molecular mass in kDa, e.g. Cx32, Cx43 and Cx45 [8].
Each Cx shows tissue- or cell-speciﬁc expression, andmost organs and
many cell types express more than one Cx [8]. Due to the fact that Cxs
can oligomerize with other Cxs, a wide range of different CxHcs can be
formed [9]. The large number of possible Cx combinations in each
CxHc results in a structural basis for functional heterogeneity of GJs
that will probably be the basis for a functional heterogeneity as well.
Normal neutrophils, monocytes, macrophages and hematopoietic
stem cells express Cx43 and usually additional Cxs (see [10], and
references therein). Bone marrow stromal cells also express different
Cxs including Cx43 and Cx45 [11,12]. GJs and Cxs are therefore likely
to participate in the regulation of normal hematopoiesis [13]. The
functional importance of GJs and Cxs in carcinogenesis is alsoFig. 1. The ﬁgure illustrates two adjoining cells connected by one gap junction
transferring small signaling molecules, e.g. Ca2+, cAMP and IP3 (●). The ﬁgure also
shows one CxHc in each cell membrane that can either connect and thereby create
another gap junction, or function as a communication channel with the intercellular
space. Both these mechanisms are involved in the regulation of neighboring cells,
including apoptosis and cell growth.illustrated by the detection of abnormal or defective GJ communica-
tion in various solid tumors including liver, bladder, breast and
prostate cancers [14] (Table 1). Even though their role in carcino-
genesis is not clear, it is possible that Cxs and GJs are involved in both
tumor growth regulations, tumor cell migration and metastasis as
thoroughly described in a recent review [15].
3. The roles of connexins in AML
Leukemia is an aggressive malignancy where both disease
development and chemosensitivity seem to be regulated by neigh-
boring stromal cells, i.e. the cells that form the hematopoietic stem
cell niche [1]. As will be described below, it seems likely that GJs are
involved in the communication between AML and stromal cells during
disease development.
3.1. The functional role of Cxs in AML cells
Studies of both the HL-60 and PLB-985 AML cell lines have shown
that direct contact with KM-102 bone marrow stromal cells inhibits
AML cell differentiation [16] (Table 2), and dye transfer studies
suggest that this effect was associated with the formation of
functional GJs [16]. Studies of both normal and leukemic bone
marrow cells have demonstrated the formation of Cx43 GJs between
stromal and hematopoietic cells, and Cx43 GJs were upregulated in
AML bone marrows [17]. Formation of functional GJs was also
detected during coculture of the murine stromal cell S17 and the
lymphoblastic leukemic cell line CCRF-CEM [18]. These studies
showed that the GJ coupling between the stromal and leukemicTable 1
Aberrant connexin expression/function in various tumors.
Disease Cx function
Liver cancer Cx32 – mostly located to the cytoplasm
Cx43 – aberrant expression
Bladder cancer Cx26 – loss
Cx43 – variable expression
Prostate cancer Cx32 – decreased expression
Cx43 – decreased expression
Breast tumor Cx26 – upregulated
Cx43 – heterogeneous expression
Lung cancer Cx43 – decreased expression
Low dye-transfer
The table presents a short overview of aberrant connexin expression and function in
malignant diseases. The table is based on [14].
Table 2
Effects of Cx/GJ in AML.
Cells/Animal Cx/GJ Function Reference
AML BM Cx43 + GJ Expression ↑ 16
U937 Cx43 mRNA AML1-ETO induced expression ↑ 18
Primary cells Cx43, Cx45 Membrane expression ↑ np
HL-60 GJ Differentiation ↓ 15
HL-60, KG1 GJ Cell growth ↓ 17
U937 Cx43 Cell growth ↓ 18
Mice Cx32-KO Increased risk of leukemic incidence 20
The table presents an overview of functional interactions between connexins and AML
cells. BM, bone marrow; KO, knock-out; np, not published.
Table 3
Functional interactions between cytotoxic drugs and Cx/GJ.
Drug Cx/GJ Function Reference
Methotrexate GJ Cell viability ↑ 17
GJ Apoptosis ↓ 17
Doxorubicin Cx43 Bcl-2 expression ↓ 21
GJ Intercellular communication ↓ 22
Cx43 Expression ↓ 23
Arsenic trioxide GJ Intercellular communication ↓ 24
Retinoic acid Cx43 Expression ↑ 25,26
GJ Intercellular communication ↑ 25,26
Cx32 Cx phosphorylation ↑ 25
The table presents an overview of functional interactions between connexins and
different chemotherapeutic drugs commonly used in AML therapy.
Table 4
Functional interactions between intracellular pathways and Cx/GJ.
Pathway Cx/GJ Function Reference
Src Cx43 Cell survival ↑ 29
Cx43 + GJ Opening ↓ 30,31
Cx32 Apoptosis ↓ 32
MAPK Cx43 Expression ↑ 38
Cx43 + GJ Intercellular communication ↓ 39,40
Cx phosphorylation
Cx43 Endocytosis ↓ 41
Cx43 + GJ Uncoupling ↓ 42
Wnt/β-catenin Cx43 Expression ↑ 52,53
Cx43 Protein levels (by G-CSF) ↑ 55
PI3K/AKT Cx32 mRNA expression ↓ 62
Cx40 Expression ↑ 63
Cx43 Expression ↓ 63
PKA GJ Intercellular communication, ↑ 28
Assembly of new GJs
Cx40 Expression ↑ 63
Cx43 Expression ↓ 63
PKC Cx43 Intercellular communication, ↓ 28
Cx phosphorylation
Cx43 + GJ Formation ↓ 28
The table presents an overview of functional connections between connexins and
different signaling pathways that may connect connexins to leukemogenesis and
chemosensitivity in AML.
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phase of the cell cycle. This effect was abrogated by carbenoxolone
that inhibits GJ-communication. Importantly, these anti-proliferative
effects of GJ coupling were also detected for the AML cell lines HL-60
and KG1 [18]. In contrast to these results, functional GJ was not found
between the murine S17 stromal cells and murine B-lineage cells
harvested from BALB/cAn mice bone marrows [11], suggesting that
the GJ communication between stromal and leukemic cells depends
on the stromal and/or leukemic cell phenotype.
The t(8;21)(q22;q22) translocation, which encodes the AML1-ETO
hybrid protein, is detected in 12% of patients with de novo AML [19].
Induced expression of the AML1-ETO fusion gene in the AMLU937 cell
line upregulated Cx43 mRNA levels [19]. The upregulation was
possibly caused by altered signaling through the c-Jun N-terminal
kinase pathway [20], and increased Cx43 expression directly inhibited
the leukemic cell growth whereas suppression of Cx43 with small
interfering RNA overcomes the growth-inhibitory effect of AML1-ETO
in leukemic cells [19]. This growth-inhibitory effect of Cx43 may
increase chemosensitivity and contribute to the good prognosis with
high AML-free survival after chemotherapy for patients with t(8;21).
Nonetheless, the small interfering RNAwill also inhibit the expression
of CxHcs leaving open the question whether the growth-inhibitory
effect of AML1-ETO in leukemic cells is mediated by Cx43 alone, only
CxHcs or functional GJs. A role of Cxs in leukemogenesis is further
supported by studies in knock-out animal models; Cx32 knock-out
mice show an increased incidence of hematopoietic malignancies
after treatment with the genotoxic chemical methylnitrosourea
compared to wild-type mice [21].
We have analyzed the mRNA levels and membrane molecule
expression of different Cxs in primary human AML blasts. The mRNA
levels of Cx32 and Cx43 showed low expression for a large majority of
patients, but a subset of patients expressed detectable surface levels of
Cx32, Cx37, Cx43 and Cx45 (unpublished data). Taken together, these
observations suggest that Cxs are important for disease development
in AML, possibly by mediating growth-regulatory signaling from
neighboring stromal cells (Table 2).
3.2. Connexins and chemosensitivity
Very few studies have investigated the possible importance of Cxs
and GJ communications for chemosensitivity of malignant cells
(Table 3). Cx43 expression increased the sensitivity of human glio-
blastoma cells to etoposide, paclitaxel and the anthracyclin doxo-
rubicin, and this increased chemosensitivity was associated with
decreased expression of anti-apoptotic Bcl-2 [22]. This observation,
together with the results from AML1-ETO induced Cx43 expression in
AML cells (above) [19], suggests that expression of this particular Cx
decreases proliferation and increases chemosensitivity.
Doxorubicin has also been associated with decreased GJ-commu-
nication in WB-F344 rat-liver epithelial cells, in which the Cx43
subtype dominates [23]. This effect of doxorubicin was mediated via
the epidermal growth factor (EGF) receptor that activated the
extracellular signal-regulated kinase (ERK)-1 and ERK-2 [23]. Doxo-rubicin treatment of the breast cancer cell line MCF-7 was associated
with increased apoptosis and decreased Cx43 expression, particularly
when doxorubicin was added in combination with docetaxel [24].
Functional GJs also protect the lymphoblastic leukemic cell line CCRF-
CEM against methotrexate induced cell death when co-cultured with
the stromal cell line S17 [18]. Thus, there seem to be an association
between Cx43 expression and regulation of apoptosis, but the
molecular explanations are not known.
Arsenic trioxide, which is currently approved for the treatment of
acute promyelocytic leukemia (APL), seems to inhibit GJ-communi-
cation between vascular endothelial cells [25]. On the other hand,
retinoic acid can increase the Cx43 membrane expression and GJ
intercellular communication in the human Hep G2 and murine 3T3
cells [26,27]. The Cx32 membrane expression was not altered, but
Cx32 phosphorylation was increased after in vitro retinoic acid
treatment [26]. Taken together, these observations suggest that reti-
noic acid can regulate GJ communication at different levels, and
increased Cx43 expression may be important for the anti-leukemic
effect of all-trans retinoic acid (ATRA) in combination with conven-
tional chemotherapies in APL.
Although few, these observations show that chemotherapeutic
drugs commonly used in AML treatment can affect Cxs and GJs. Most
studies suggest that Cx43 expression increases chemosensitivity and
this seems to be true both for anthracyclins and ATRA. Cx32 may have
a similar effect. In contrast, other studies suggest that decreased
communication through GJs may be a part of the anticancer effect for
several chemotherapeutics. The most likely explanation for these
apparently conﬂicting results is that the effect of GJs on cell growth
Fig. 3. The ﬁgure gives an overview of possible interactions between various
intercellular pathways and connexins. Based on the literature (see text), connexin
regulation is clearly affected at least by the Src, MAPK, PI3K/AKT, PKA, PKC andWnt/β-
catenin pathways in different cell types. These pathways are under control of various
hematopoietic growth factors including the Flt3- andWnt-ligands. Connexins may also
alter the activity of intercellular pathways via its interaction with Src.
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explanation could be cell-speciﬁc differences, but at least for Cx43
this seems less likely because the chemosensitizing/growth-inhibi-
tory effect was detected in different cells.
4. Connexins and intracellular pathways in AML
Several intracellular signaling pathways are involved in the
regulation of Cx expression and function in leukemic cells (over-
viewed in Table 4 and Fig. 3). Here we show that different signaling
pathways may connect Cx to leukemogenesis and possibly also
chemosensitivity in AML.
4.1. Src pathways
Src is an intracellular non-receptor family of kinases that regulates
intracellular signaling [28]. Src can promote neoplastic transformation
and seems to be involved in the progression of diverse malignancies
including leukemias, lymphomas and myeloma [28,29]. As recently
reviewed [29], Src can alter the activation of Cx43 both directly as well
as indirectly via several other kinases including mitogen activated
protein kinase (MAPK). Interestingly, previous studies have demon-
strated that Cx43 CxHcs can interact with Src and promote cell
survival by mechanisms involving MAPK [30]. The Src pathway can
also inhibit Cx43-based GJ communication [31,32]. All together, these
observations suggest that there seem to be a bidirectional crosstalk
between Cx43 and Src (Fig. 3) at least in certain cells, but it is not
known whether this can be seen in AML. The Src inhibitor PP1
potentiated Cx32-dependent cell growth suppression in Cx32-
tranfected renal cells and apoptosis was then induced through
reduction of anti-apoptotic Bcl-2 and Bcl-xL [33]. Thus, Src seems to
be involved in the regulation of various Cxs. However, it is important
to note that the role of Src in the regulation of Cx43 and Cx32 might
not be comparable due to their different structures, biochemistry, e.g.
their phosphorylation status, and the fact that the Src regulation of
different Cxs may be cell speciﬁc and involve different signaling
pathways.
The Src-Cx/GJ-interactions may be involved in leukemogenesis via
the Fms-like tyrosine kinase-3 (Flt-3). Flt3 is a hematopoietic growth
factor receptor that promotes survival and proliferation of myeloid
precursors, and mutations of Flt-3 have been detected in approxi-mately 30% of AML patients [34]. Flt-3-internal tandem duplications
(ITD) are common, and these mutations are associated with an
adverse prognosis [34]. Different Src subtypes interfere with the
maturation process of Flt-3 by lowering the expression of the
glycosylated high molecular weight form of Flt-3 and increasing the
low molecular weight form; this is a kinase-dependent process [35].
On the other hand, Flt-3 ligation can activate the Src kinase [36]. The
Flt-3 pathway may thereby affect Cx-mediated communication
indirectly through its crosstalk with Src (Fig. 3).
Finally, ATRA-induced differentiation of the leukemic cell lines NB-
4, HL-60 and U937 and primary AML cells is inhibited by Src [37]. This
observation suggests that Src mediates chemoresistance, but it is not
known whether this Src-mediated effect also involves inhibition of
retinoic acid-induced Cx43 expression (see above).
4.2. MAPK/MEK/ERK pathways
The MAPK and MEK/ERK pathways are a highly complex cascade
reaction transmitting signals from different ligands [38]. As already
mentioned, Src is connected to MAPK that can phosphorylate Cx43
[29]. Several observations suggest that there exist direct functional
interactions between Cxs and the MAPK/MEK/ERK pathways. Studies
in various cell types have demonstrated that these pathways are
involved in Cx43 upregulation by Angiotensin II [39], Cx43 phos-
phorylation with decreased GJ communication [40,41], Cx43 endocy-
tosis induced by the carcinogen Lindane [42] and Cx43 GJ uncoupling
induced by EGF [43]. The ERK pathway also seems to be involved in
GJ-independent survival signaling by Src [30].
The relevance of these pathways in AML has been shown in several
reports describing that a subset of AML cells show activated MAPK
[44,45], suggesting that MAPK may be involved in leukemogenesis
[44]. MEK and ERK are also activated in AML cells [46], and the MEK
activation blocker PD98059 decreases both growth and survival of
AML cell lines as well as primary cells [47]. The ERK pathway seems to
cooperate with Flt-3 in regulation of cell survival [45]. Taken together,
the available observations suggest that MAPK and MEK/ERK path-
ways are involved in downregulation of Cx expression and/or GJ
communication in AML.
4.3. Wnt/β-catenin pathway
The Wnt/β-catenin pathway is one of at least three pathways
activated upon Wnt receptor ligation and initiates complex intracel-
lular events involving a wide range of mediators [48]. Wnt signaling is
involved in control of self-renewal and is thus an important regulator
of hematopoietic stem cells [48]. The pathway is also activated in AML
and this aberrant activation may contribute to the malignant
phenotype [49]. β-catenin is expressed by primary AML cells for a
majority of patients, and the level correlates with the capacity of
clonogenic proliferation and cellular self-renewal [50]. Primary AML
blasts with Flt-3-ITD express high levels of β-catenin, and the
leukemogenic effects of Flt-3-ITD seem to be mediated in part by
the Wnt signaling pathway [51]. This pathway is in addition involved
in AML chemosensitivity regulation [52].
The Wnt/β-catenin pathway interferes with Cx43 that acts as a
functional target ofWnt1 signaling [53]. Cx43 expression is increased
by Wnt overexpression [53,54] probably through regulation at the
transcriptional level [53,55]. In cardiomyocytes, granulocyte-colony
stimulating factor (G-CSF) increased both the β-catenin (possibly via
Wnt activation) and Cx43 protein levels [56], suggesting a coordi-
nated regulation of at least this particular Cx and components in the
Wnt/β-catenin pathway. In addition, a direct association between
Cx43 and β-catenin is demonstrated in rat cardiomyocytes where β-
catenin seems to be required for Cx43 transport to the cell membrane
[57].
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calcium levels and thereby modulates the calcium-sensitive proteins,
including calcium/calmodulin-dependent protein kinase II and
protein kinase C (PKC) [58]. GJs are able to coordinate intercellular
calcium propagation [59] and Cx32 is identiﬁed with calmodulin-
binding domains [60] and may therefore represent a functional
connection of Cxs to this pathway.
Taken together, these observations show that the Wnt/β-catenin
pathway is important in AML. This pathway can interfere with Cx
expression, Cx43 in particular, and these interactions may thus alter
functional characteristics of AML cells.
4.4. PI3K/AKT, PKA and PKC
Phosphoinositide 3-kinase (PI3K) is an important signaling
component downstream to several growth factor receptor tyrosine
kinases that act via the second messenger PIP3 to activate protein
kinase B (AKT) [61]. The PI3K/AKT pathway is involved in regulation
of proliferation and survival for many cells [61], including clonogenic
AML cell growth [62] and AML cell survival [63,64], and the AKT
pathway seems to cooperate with Flt-3 in cell survival regulation in
some AML cells [45]. Interestingly, the Cx32 mRNA levels are
downregulated in AKT transfected rat hepatocytes by a mechanism
involving the integrin-linked kinase pathway [65]. The PI3K/AKT
pathway is also involved in the regulation of Cx40 and Cx43
expression in adenovirus vector E4 infected endothelial cells [66]. In
these cells, Cx40 expression was increased, whereas Cx43 expression
was suppressed by the adenovirus infection, and both these effects
were abrogated both by the PI3K inhibitor LY294002 and the protein
kinase A (PKA) inhibitor H89 [66]. PKA can increase GJ communica-
tion and facilitate the assembly of new GJs [29]. The role of PKA is not
well characterized in AML, but its activity is upregulated in ATRA
treated NB-4 AML cells [67] and it is important for the anti-apoptotic
effect of the Flt3-ITD [68].
As reviewed elsewhere [29], Src can directly or via diacylglycerol
and mobilized calcium activate protein kinase C (PKC). Activated PKC
can phosphorylate Cx43 and, in most experiments, reduce GJ
communication. PKC-γ can reduce Cx43 GJ formation in lens epithelial
cells, PKC-α and β can inhibit ﬁbroblasts coupling and PKC-ɛ can
associate with Cx43 in cardiomyocytes (see [29] and references
therein). PKC is detected in a subset of primary AML cells and PKC
activation is associated with poor survival [69]. Interestingly, ingenol
3-angelate (PEP005), which is a PKC agonist, induces apoptosis in
AML cells [70].
Altogether, the PI3K/AKT, PKA and PKC signaling pathways can
interact with regulations of Cx expression, Cx40 and Cx43 in
particular, and GJ communication. These pathways represent possible
therapeutic targets in AML, but it is not knownwhethermodulation of
Cx/GJ is important for the anti-leukemic effects of this therapeutic
strategy.
4.5. Growth factor initiated signaling
Intracellular pathways are usually directly or indirectly controlled
by a wide range of mediators including growth factors. Diverse
hematopoietic growth factors activate the Src, PI3K and MAPK/ERK
systems (Fig. 3) including erythropoietin, thrombopoietin, stem cell
factor, G-CSF, granulocyte-macrophage-CSF (GM-CSF), interleukin
(IL)-3, platelet-derived growth factor (PDGF), vascular endothelial
growth factor (VEGF), EGF, insulin-like growth factor (IGF)-1, tumor
necrosis factor (TNF)-α and ﬁbroblastic growth factor (FGF) [28,71–74].
These cytokines, and possibly others as well, may thereby be involved
in the regulation of Cx and GJ intercellular communication. This has
been demonstrated for some of them: (i) PDGF inhibits GJ commu-
nication in theﬁbroblast T3TA31 cell line [75] andmesangial cells [74],
(ii) G-CSF increases Cx43 expression and sustain GJ functions incardiomyocytes [56], (iii) FGF-1 can increase membrane permeability
through CxHcs in HeLa cells that express Cx43 or Cx45 [76], (iv) TNFα
together with interferon-γ (INFγ) increases Cx43 expression and GJ
communication in human monocytes [77] and (v) IL-1 inhibits GJ
communication in murine stromal cells expressing Cx43 [11].
Obviously, a wide range of hematopoietic growth factors are potential
regulators of Cx and GJ functions that are possibly important both for
normal and neoplastic hematopoiesis.
The PKC activator PEP005 (see over) can increase the release of
several cytokines both by AML cells and by neighboring non-leukemic
cells, e.g. INFγ and TNFα release by immunocompetent cells [78].
Several of the Cx-affecting growth factors are available in the AML
microenvironment and affect proliferation and constitutive cytokine
secretion by primary human AML cells [79–81]. Autocrine and
paracrine mechanisms may therefore interact with Cxs in AML. This
suggest, as recently reviewed for growth factors [82], that Cxs may
participate in mechanisms determining leukemic cell chemosensitiv-
ity and possibly the risk of relapse from minimal residual disease.
5. Gap junction- and Hemichannel-independent effects of
connexins
As reviewed elsewhere, Cxs can alter cellular functions indepen-
dently of both GJs and CxHcs [83,84]. To the best of our knowledge,
these effects have not been studied in AML, although they may be
involved in leukemogenesis or other AML functions.
5.1. Communication through CxHcs
CxHcs can affect neighboring cells by their release of different
substances, e.g. adenosine triphosphate (ATP) and nicotinamid
dinucleotid (NAD+), into the extracellular space [83]. ATP can then
bind its P2 purinergic receptors and thereby induce the production of
IP3 that in turn raises the intracellular Ca2+ levels and initiate Ca2+
waves [83]. Extracellular ATP suppresses the growth and induces cell
differentiation of the HL-60 AML cell line, the latter partly by P2
receptor ligation and PKA activation [85]. Released NAD+ can be
converted into cyclic ADP-ribose by the ectoenzyme CD38 and then
reenter neighboring cells and trigger Ca2+ release from the endoplas-
matic reticulum [83]. However, leukemic stem cells are generally
CD38 negative, so this CxHc effect might therefore be less important
in AML.
CxHcs seem to have pro-apoptotic effects that aremediated trough
several mechanisms including prolonged opening of the hemichan-
nels leading to imbalance of ionic gradients [86]. However, CxHcs may
also mediate anti-apoptotic effects [86]. This is observed in osteocytic
and osteoblastic cells where opening of their Cx43 CxHcs by
biphosphonates exerts anti-apoptotic effects that are mediated by
Src kinase and ERKs [87]. Thus, cells localized to the endosteal stem
cell niche, including leukemic cells, may interact via CxHcs and
thereby alter the physiology of the niche.
5.2. CxHc-independent effects of connexins
The cytoplasmic carboxyl domain of Cx43 can suppress the growth
of both the Neuro 2a cell line aswell as the human osteosarcomaU2OS
cell line [75,88]. In transfected HeLa cells, the carboxyterminal tail of
Cx43 inhibits cell proliferation, suggesting thatmembrane localization
of the protein is not required for its antiproliferative effects [89].
Interestingly, these C-terminals were localized to the nucleus both in
HeLa cells and cardiomyocytes, suggesting that these parts of Cx43
may be involved in regulation of gene expression. However, the
signiﬁcance of these experiments implies that the C-terminals are
physiological active, which remains to be determined. Studies of
Cx45.6 in chick eye lens further suggest that Cxs may be involved GJ-
independent differentiation [90]. Although none of these studies are
6 B. Foss et al. / Biochimica et Biophysica Acta 1798 (2010) 1–8linked to AML, they suggest that Cxs may function as intracellular
regulators of both proliferation and possibly differentiation.
6. Connexins may affect AML cell death mechanisms
As previously reviewed by Bruserud et al. [91], several studies
suggest that the regulation of apoptosis is important for outcome after
intensive chemotherapy in AML. There are several indications that Cx
are involved in AML (Table 2), and apoptosis represents one candidate
mechanism that may be affected. Diverse functionality for Cxs in cell
death control has been demonstrated or suggested, including
apoptosis-related gene expression that may occur independently of
GJ activity [92,93]. Cx43 is the predominant isoform in many tissues
and has been particularly studied in this context, but other Cxs such as
Cx26 and Cx32 may also be involved [94].
Cxs can interfere with cellular homeostasis, injury responses and
survival processes via several mechanisms. As building blocks of GJs,
they facilitate transfer of cell fate signals. Such an explanation has
been used to describe the clustered cell death in some cancer cell
populations [95] and spread of cell death in ischemia [96]. As far as we
know, it remains unclear if local transfer of death signals occurs
between adjacent cells of various types, e.g. between leukemic and
stromal cells in bone marrow. There are many candidate modulators
of survival and death that can pass through GJs, including apoptosis
effectors, second messengers, nutrients and toxins. Whether this
eventually will inﬂuence cell viability seems to be determined by the
type and physiological status of the participating cells. Ca2+, IP3 and
cAMP have all been suggested as potential death messengers when
transferred via gap junctions [93]. Ca2+ contributes to the regulation
of apoptotic cascades and mitochondrial permeability [97], whereas
IP3 can trigger the release of Ca2+ and thereby have pro-apoptotic
effects [98]. Finally, effects of cAMP are mediated via cAMP-
dependent kinase, and cAMP analogs can induce cell death in
leukemic cells [99]. In contrast to the transfer of death signals, it has
also been suggested that gap junctions promote survival of adjacent
cells either by providing nutrients, ATP or antioxidants, or by
restricting the ﬂux of harmful compounds such as toxins and reactive
oxygen species (ROS) [86]. In total, the physiological outcome of the
transport of cell fate modulators through GJs seems to depend on the
cellular context and the balance between different signaling
pathways.
The roles of Cxs in cell death/survival do not necessarily involve GJ
activity. Several reports suggest that Cxs mediate autonomous
regulation. Cx26 was found to regulate gene expression in breast
tumor cells via unknown GJ-dependent as well as -independent
mechanisms [100]. Phosphorylation of serine 262 in Cx43 has been
demonstrated to regulate DNA synthesis in cardiomyocytes appar-
ently independent of GJ formation [101]. Cx43 has also been localized
to the nucleus and the mitochondria where it obviously serves other
roles than GJ formation [92], but it remains an open question whether
or not it forms hemichannels in the mitochondrial membrane [102].
The mitochondria link processes of cellular metabolism and cell death
pathways, and a large number of reports have implicated these
organelles in the process of carcinogenesis [103].
7. Conclusion
The role of Cxs in AML is not well characterized. Still, it seems
evident that different Cxs, at least Cx32 and Cx43, are expressed by
AML cells and canmediate growth regulation possibly via interactions
with stromal cells. Different chemotherapeutic drugs commonly used
in AML therapy can alter Cx expression and GJ function of various
cells. Cxs might thus be involved in leukemogenesis and chemosensi-
tivity in AML.
Various hematopoietic growth factors and intracellular pathways
important in the regulations of leukemic cell functions and develop-ment are able to alter Cx regulations in various cells. GJs, CxHcs and
Cxs are in addition active participants in apoptosis regulation.
Therefore, Cxs are clearly having the potential to interfere with
diverse signaling pathways of clinical relevance in human AML.References
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